Gastric Cancer Clinical Trial
Official title:
The Value of Serum Trefoil Factor Family 3 (TFF3) in Diagnosis of Gastric Cancer
Gastric cancer (GC), is a cancer developing from the inner lining of the stomach .The most
common cause is infection by the bacterium Helicobacter pylori,which accounts for 60% of
cases.
Human pepsinogens (HP) are proenzymes for pepsin; digestive enzymes produced by gastric chief
cells, classified into two groups: pepsinogen I (PGI) and pepsinogen II (PGII), humen
pepsinogens considered promising serological biomarkers for the screening of atrophic
gastritis and gastric cancer.
The trefoil factor family (TFF) of peptides comprises small (12-22kDa) molecules that are
secreted by the mammalian gastro-intestinal tract.Trefoil factor family 3 (TFF3) is a more
stable non invasive biomarker of gastric cancer risk even in early gastric cancer.
Gastric cancer (GC), is a cancer developing from the inner lining of the
stomach.Approximately half of the gastric cancer cases are diagnosed during advanced stages.
One of the reasons for this is the invasiveness of esophagogastroduodenoscopy (EGD) screening
examinations that leads to patients avoiding necessary tests .
The most common cause is infection by the bacterium Helicobacter pylori (H.pylori),which
accounts for 60% of cases.
The development of tools for the early diagnosis of gastric cancer and precancerous lesions
of gastric cancer is important for reducing mortality, increasing survival rates, and
improving quality of life.
Endoscopy and biopsy are the reference standards for diagnosis and screening of gastric
cancer, but their use is limited for population-wide screening due to their
invasiveness.Subsequently, it is necessary to identify novel, simple, cost-effective and
manipulable screening methods for gastric cancer.
Human pepsinogens (HP) are proenzymes for pepsin, a digestive enzymes produced by gastric
chief cells,biochemically and immunochemically classified into two groups: pepsinogen I (PGI)
and pepsinogen II (PGII), humen pepsinogens considered promising serological biomarkers for
the screening of atrophic gastritis and gastric cancer,serum pepsinogen test provides a
valuable method for detecting gastric cancer and atrophic gastritis.
The limitation of the pepsinogen test as a non invasive serologic biomarker screening method
is that the optimal cut-off value could be affected by several factors, age, gender, and the
test method itself.
The trefoil factor family (TFF) of peptides comprises small (12-22kDa) molecules that are
secreted by the mammalian gastro-intestinal tract. TFFs constitute a family of three peptides
(TFF1, TFF2, and TFF3) that are widely expressed in a tissue-specific manner in the gastro-
intestinal tract. Trefoil factor family 3 (TFF3) is expressed in the goblet cells of the
small and large intestines as well as the intestinal metaplasia in the stomach.
The trefoil factor family (TFF) plays a key role in the maintenance of mucosal integrity, and
plays an impotant role in oncogenic transformation, growth, and metastatic extension of
common human solid tumors, including gastric cancer.
SerumTFF3 showed good diagnostic power in both of H. pylori positive and H. pylori-negative
gastric cancer and its serum levels were significantly higher in patients with advanced
gastric cancer than that in patients with early gastric cancer.
H. pylori organisms live in gastric mucosa, and attach to epithelial cells of stomach
.Because trefoil factor family 3 is not expressed in epithelial cells of the stomach and is
only expressed in the intestinal goblet cells of the metaplasia of gastric cancer , serum
trefoil factor family 3 levels are less influenced by H. pylori infection , eradication,
aging, and sex ,therefore, serum trefoil factor family 3 is a more stable non invasive
biomarker of gastric cancer risk even in early gastric cancer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |